Surface Oncology (NASDAQ:SURF) and BIO-TECHNE (NASDAQ:TECH) Financial Survey

Surface Oncology (NASDAQ:SURF) and BIO-TECHNE (NASDAQ:TECH) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, institutional ownership, profitability, valuation and earnings.

Analyst Recommendations

This is a breakdown of current recommendations for Surface Oncology and BIO-TECHNE, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Surface Oncology 0 0 2 0 3.00
BIO-TECHNE 0 2 6 0 2.75

Surface Oncology currently has a consensus target price of $23.00, indicating a potential upside of 709.86%. BIO-TECHNE has a consensus target price of $201.25, indicating a potential downside of 6.14%. Given Surface Oncology’s stronger consensus rating and higher possible upside, analysts plainly believe Surface Oncology is more favorable than BIO-TECHNE.

Dividends

BIO-TECHNE pays an annual dividend of $1.28 per share and has a dividend yield of 0.6%. Surface Oncology does not pay a dividend. BIO-TECHNE pays out 31.4% of its earnings in the form of a dividend.

Insider & Institutional Ownership

59.0% of Surface Oncology shares are held by institutional investors. Comparatively, 92.7% of BIO-TECHNE shares are held by institutional investors. 33.0% of Surface Oncology shares are held by company insiders. Comparatively, 3.8% of BIO-TECHNE shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Surface Oncology and BIO-TECHNE’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Surface Oncology $59.42 million 1.33 -$6.60 million ($0.33) -8.61
BIO-TECHNE $642.99 million 12.63 $126.15 million $4.07 52.68

BIO-TECHNE has higher revenue and earnings than Surface Oncology. Surface Oncology is trading at a lower price-to-earnings ratio than BIO-TECHNE, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Surface Oncology has a beta of 2.4, indicating that its stock price is 140% more volatile than the S&P 500. Comparatively, BIO-TECHNE has a beta of 1.17, indicating that its stock price is 17% more volatile than the S&P 500.

Profitability

This table compares Surface Oncology and BIO-TECHNE’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Surface Oncology -148.15% -38.97% -22.92%
BIO-TECHNE 17.15% 13.53% 8.35%

Summary

BIO-TECHNE beats Surface Oncology on 11 of the 16 factors compared between the two stocks.

Surface Oncology Company Profile

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies. The company develops human immunoglobulin isotype G4 monoclonal antibodies, including SRF231 inhibiting CD47; NZV930 inhibiting CD73; SRF617 inhibiting CD39; and SRF388 targeting interleukin 27. It also develops various earlier stage programs that targets other critical components of the tumor microenvironment, including regulatory T cells and natural killer cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies. Surface Oncology, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents. It also provides various products, which serves as predictive biomarkers and therapeutic targets for various human diseases and conditions, such as cancer, autoimmunity, diabetes, hypertension, obesity, inflammation, neurological disorders, and kidney failure. The Protein Platforms segment offers Biologics tools for researchers to interrogate protein purity and identify contaminants during the development and production of biologics; Western blot, an assay for protein analysis and identification; SimplePlex platform, an enzyme-linked immunosorbent assay for use in research and clinical diagnostics; and Single Cell Western platform to elucidate the properties of individual cells to understand cell behavior. The Diagnostics segment provides blood chemistry and gas quality controls, hematology instrument controls, diagnostic immunoassays, and other bulk and custom reagents for the in vitro diagnostic market. Bio-Techne Corporation has a strategic cooperation agreement with Micropoint Bioscience. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. It has strategic partnership with NanoString Technologies. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.

Receive News & Ratings for Surface Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surface Oncology and related companies with MarketBeat.com's FREE daily email newsletter.